Kazuaki Takabe Selected Research

Colitis-Associated Neoplasms

11/2018	Upregulation of phosphorylated sphingosine kinase 1 expression in colitis-associated cancer.
1/2014	Sphingosine-1-phosphate in chronic intestinal inflammation and cancer.
1/2013	Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazuaki Takabe Research Topics

Disease

153	Neoplasms (Cancer) 06/2024 - 08/2008
109	Breast Neoplasms (Breast Cancer) 05/2024 - 08/2008
30	Neoplasm Metastasis (Metastasis) 03/2023 - 02/2012
21	Inflammation (Inflammations) 03/2024 - 01/2013
20	Triple Negative Breast Neoplasms 03/2024 - 01/2017
10	Carcinogenesis 06/2023 - 08/2008
9	Stomach Neoplasms (Stomach Cancer) 02/2024 - 08/2008
9	Pancreatic Neoplasms (Pancreatic Cancer) 03/2023 - 10/2016
9	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 08/2010
7	Hepatocellular Carcinoma (Hepatoma) 04/2024 - 09/2016
6	Adenocarcinoma 01/2023 - 01/2019
6	Colonic Neoplasms (Colon Cancer) 01/2021 - 08/2008
5	Microsatellite Instability 11/2022 - 10/2017
5	Lymphatic Metastasis 08/2021 - 05/2012
4	Cholestasis 03/2023 - 11/2016
4	Obesity 02/2023 - 11/2017
3	Hypoxia (Hypoxemia) 08/2022 - 01/2020
3	Cicatrix (Scar) 08/2020 - 07/2019
3	Colitis-Associated Neoplasms 11/2018 - 01/2013
3	Ulcerative Colitis 01/2016 - 01/2013
3	Colitis 01/2016 - 01/2014
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 10/2023 - 01/2022
2	Infections 06/2023 - 01/2023
2	Peritoneal Neoplasms 03/2023 - 10/2016
2	Cholangiocarcinoma 03/2023 - 01/2017
2	Chronic Obstructive Pulmonary Disease (COPD) 12/2022 - 08/2007
2	Disease Progression 01/2022 - 09/2014
2	Pathologic Complete Response 01/2021 - 12/2020
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 03/2018
2	Pathologic Processes 04/2020 - 12/2016

Drug/Important Bio-Agent (IBA)

43	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 04/2024 - 08/2008
32	Biomarkers (Surrogate Marker)IBA 03/2024 - 08/2010
21	sphingosine kinaseIBA 01/2021 - 08/2008
20	LipidsIBA 04/2024 - 11/2011
16	Proteins (Proteins, Gene)FDA Link 04/2024 - 08/2008
16	SphingolipidsIBA 10/2023 - 07/2009
15	EnzymesIBA 12/2022 - 01/2017
14	Estrogen ReceptorsIBA 01/2022 - 02/2013
11	MicroRNAs (MicroRNA)IBA 01/2023 - 10/2017
10	SphingosineIBA 10/2023 - 01/2014
9	RNA (Ribonucleic Acid)IBA 01/2024 - 01/2017
9	Fingolimod Hydrochloride (FTY720)FDA Link 03/2023 - 11/2011
9	Messenger RNA (mRNA)IBA 01/2022 - 08/2008
8	Hormones (Hormone)IBA 02/2024 - 12/2018
8	CytokinesIBA 01/2024 - 05/2013
8	Interleukin-6 (Interleukin 6)IBA 07/2022 - 01/2014
8	Phosphotransferases (Kinase)IBA 01/2021 - 01/2014
8	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 10/2017
7	Immune Checkpoint InhibitorsIBA 03/2024 - 12/2017
7	CeramidesIBA 10/2023 - 01/2016
7	Phenobarbital (Luminal)FDA Link 01/2022 - 01/2017
6	InterferonsIBA 01/2024 - 09/2020
6	human ERBB2 proteinIBA 10/2023 - 02/2013
6	Bile Acids and Salts (Bile Acids)IBA 03/2023 - 01/2016
6	Mechanistic Target of Rapamycin Complex 1IBA 01/2023 - 01/2021
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2024 - 11/2021
5	Sphingosine-1-Phosphate ReceptorsIBA 03/2023 - 11/2011
5	Estrogens (Estrogen)FDA Link 01/2022 - 01/2019
4	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 05/2013
3	Lysophosphatidic Acid ReceptorsIBA 02/2024 - 08/2008
3	Phosphates (Orthophosphate)IBA 10/2023 - 01/2016
3	NucleotidesIBA 06/2023 - 06/2020
3	Interleukin-2 (IL2)IBA 01/2023 - 05/2020
3	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2022 - 11/2017
3	Complement System Proteins (Complement)IBA 07/2022 - 01/2021
3	AndrogensIBA 01/2022 - 03/2018
3	ErbB Receptors (EGF Receptor)IBA 01/2022 - 05/2013
3	Epidermal Growth Factor (EGF)IBA 01/2022 - 08/2008
3	palbociclibIBA 01/2021 - 12/2018
3	Immune Checkpoint ProteinsIBA 01/2021 - 12/2020
3	ChemokinesIBA 01/2021 - 05/2013
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021 - 11/2019
3	Histones (Histone)IBA 09/2020 - 07/2019
3	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2018 - 02/2013
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 06/2023 - 01/2014
2	Taurocholic Acid (Sodium Taurocholate)IBA 03/2023 - 04/2015
2	salicylhydroxamic acid (SHAM)IBA 03/2023 - 06/2013
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2022 - 11/2021
2	AntigensIBA 12/2022 - 12/2017
2	Small Interfering RNA (siRNA)IBA 11/2022 - 08/2020
2	Oxygen (Dioxygen)IBA 07/2022 - 01/2021
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2019
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2022 - 07/2020
2	A-Form DNA (A-DNA)IBA 11/2021 - 01/2021
2	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 05/2019
2	Annexin A1IBA 01/2021 - 08/2019
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021 - 08/2019
2	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 12/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 12/2020
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2020 - 01/2019
2	Protein Isoforms (Isoforms)IBA 04/2020 - 01/2016
2	Everolimus FDA Link 01/2020 - 12/2018

Therapy/Procedure

40	Therapeutics 02/2024 - 08/2008
24	Neoadjuvant Therapy 03/2024 - 05/2019
23	Drug Therapy (Chemotherapy) 06/2024 - 08/2008
9	Immunotherapy 01/2023 - 01/2016
5	Precision Medicine 01/2022 - 12/2016
4	Radiotherapy 06/2024 - 09/2016
2	Oral Administration 10/2023 - 01/2016
2	Adjuvant Chemotherapy 12/2019 - 01/2017